July 29, 2014
Traverse, NS-LIJ Win Grant to Treat Osteoarthritis
Stony Brook-based Traverse Biosciences and the Feinstein Institute for Medical Research have received a $223,979 technology transfer grant to develop a new treatment for osteoarthritis.
The money comes by way of the National Institute of Health, which is funding Traverse Biosciences and the research offshoot of the North Shore-Long Island Jewish Health System to evaluate the effectiveness of Traverse’s drug, known as TRB-N0224.
Daniel Grande, director of the institute’s orthopaedic research laboratory, will lead the research for the institute, serving and collaborating with Traverse Biosciences.
Osteoarthritis is a common form of musculoskeletal disease that affects 27 million Americans, according to the Stony Brook company.
Feinstein Institute Receives $223,979 Small Business Technology Transfer Award In Partnership With Traverse Biosciences